ClinicalTrials.gg
CompletedNCT04502693Updated Mar 5, 2024Results posted

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

A Phase 3 interventional study of rMenB+OMV NZ vaccine and Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 112 sites in 7 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,657
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
2nd of 21
3,657 · median 508
Started
2020
the only one that year
Phase 3
7 of 21
none open now
Registered
19th of 21
by date
Lead sponsor
6 of 21
GlaxoSmithKline

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 19th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 10 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.

Read the detailed description

As per the feedback from the Center for Biologics Evaluation and Research (CBER), the scope of this post-marketing commitment study was extended to demonstrate the effectiveness, immunogenicity, and safety of GSK's investigational combined meningococcal ABCWY vaccine along with the rMenB+OMV NZ vaccine. Note that the rMenB+OMV and MenACWY vaccines provided to the MenB_0_2_6, MenB_0_6 group, and MenACWY group, respectively, at day 211 were only as part of the standard care of treatment and to maintain blinding. These vaccination schedules were not considered for any endpoint evaluations.

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Bexsero
  • Menveo
  • MenABCWY
  • Effectiveness
  • Invasive meningococcal disease
  • Meningitis
04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects or/and subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the subject/parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.
  • Written informed assent obtained from the subject (if applicable) prior to performing any study specific procedure.
  • A male or female between, and including, 10 and 25 years of age (i.e. 25 years + 364 days) at the time of the first vaccination.
  • Healthy subjects as established by medical history physical examination and clinical judgment of the investigator before entering into the study.
  • Subjects who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine can participate in the study, if they have received it at least 4 years prior to informed consent and assent as applicable (with the exception of meningococcal C vaccination, if the last dose of MenC was received at ≤24 months of age).
  • Female subjects of non- may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or *.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception until 30 days after completion of Visit 6.

      • A female is considered to be of non-childbearing potential prior to menarche and after natural or induced menopause. Natural menopause is recognized to have occurred after 12 consecutive months of amenorrhea for which there is no other obvious pathological or physiological cause. Induced menopause is recognized to have occurred after hysterectomy, after bilateral oophorectomy, or iatrogenic ablation of ovarian function.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Current or previous, confirmed or suspected disease caused by N. meningitidis.
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.
  • Progressive, unstable or uncontrolled clinical conditions.
  • Clinical conditions representing a to intramuscular vaccination and blood draws.
  • Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion.
  • History of any reaction or likely to be exacerbated by any component of the vaccine(s)/product(s).

    • Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM 197) and latex medicinal products or medical equipment whose use is foreseen in this study.
  • Abnormal function or modification of the immune system resulting from:

    • disorders or immunodeficiency syndromes.
    • Systemic administration of (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination until the post-vaccination 3 blood sample (Visit 6). This will mean prednisone - ≥20 mg/day (for adult subjects) or ≥0.5 mg/kg/day (for paediatric subjects), or equivalent. Inhaled and topical steroids are allowed.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
    • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination.

Prior/Concomitant therapy

  • Use of any or non-registered product other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period.
  • Previous vaccination against any group B meningococcal vaccine at any time prior to and assent as applicable.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine/ product or planned administration during the study period until the post-vaccination 3 blood sample (Visit 6).
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the vaccine/product dose(s) until the post-vaccination 3 blood sample (Visit 6). For corticosteroids, this will mean prednisone ≥20 mg/day (for adult subjects) or ≥0.5 mg/kg/day (for paediatric subjects), or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other exclusions

  • Child in care.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
  • History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator.
  • Any study personnel or immediate dependants, family, or household member.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,657 participants (actual)

Study arms

  • Experimental
    MenB_0_2_6 Group

    Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.

    Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)

  • Experimental
    MenB_0_6 Group

    Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.

    Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) · Combination Product: Placebo

  • Experimental
    ABCWY-1 Group

    Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.

    Combination Product: Placebo · Combination Product: MenABCWY-1

  • Experimental
    ABCWY-2 Group

    Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.

    Combination Product: Placebo · Combination Product: MenABCWY-2

  • Experimental
    ABCWY-3 Group

    Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.

    Combination Product: Placebo · Combination Product: MenABCWY-3

  • Active comparator
    ACWY Group

    Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.

    Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) · Combination Product: Placebo

  • Experimental
    ABCWY_Pooled

    Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Combination Product: MenABCWY-1 · Combination Product: MenABCWY-2 · Combination Product: MenABCWY-3

Interventions

  • Combination productrMenB+OMV NZ vaccine

    Drug page: 4CMenB vaccine

    rMenB+OMV NZ vaccine was administered intramuscularly.

    Also known as: Bexsero

  • BiologicalMeningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)

    Drug page: MenACWY

    MenACWY vaccine was administered intramuscularly.

    Also known as: Menveo

  • Combination productPlacebo

    Placebo was administered intramuscularly.

    Also known as: NaCl, saline solution

  • Combination productMenABCWY-1

    Lot 1 of the MenABCWY vaccine was administered intramuscularly.

  • Combination productMenABCWY-2

    Lot 2 of the MenABCWY vaccine was administered intramuscularly.

  • Combination productMenABCWY-3

    Lot 3 of the MenABCWY vaccine was administered intramuscularly.

06

What researchers measure

Primary outcomes

  1. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY

    The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.

    Time frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)

  2. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY

    The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.

    Time frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)

  3. Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV

    The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.

    Time frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)

  4. Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV

    The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.

    Time frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])

  5. Geometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWY

    Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre-specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine.

    Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)

  6. Percentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to Baseline

    Four-fold rise is defined as: If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be \>= 16 . If the pre-vaccination hSBA titer is \>= limit of detection (LOD) but \< LL of quantification (LLOQ), then post-vaccination hSBA titer should be \>= 4 times the LLOQ. If the pre-vaccination hSBA titer is \>= LLOQ, then post-vaccination hSBA titer should be \>= 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)

  7. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)

    The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)

  8. Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV

    The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])

  9. Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)

    The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains tested for MenABCWY is above 65%.

    Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)

  10. Number of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention Administration

    Assessed solicited local adverse events were injection or administration site = pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  11. Number of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention Administration

    Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the second study intervention administration occurring at Day 61

  12. Number of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention Administration

    Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the third study intervention administration occurring at Day 181

  13. Number of Participants With Any Solicited Systemic AEs After the First Study Intervention Administration

    Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  14. Number of Participants With Any Solicited Systemic AEs After the Second Study Intervention Administration

    Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the second study intervention administration occurring at Day 61

  15. Number of Participants With Any Solicited Systemic AEs After the Third Study Intervention Administration

    Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During 7 days after the third study intervention administration occurring at Day 181

  16. Number of Participants With Any Unsolicited AEs After the First Study Intervention Administration

    Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During the 30 days after the first study intervention administration occurring at Day 1

  17. Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration

    Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During the 30 days after the second study intervention administration occurring at Day 61

  18. Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration

    Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: During the 30 days after the third study intervention administration occurring at Day 181

  19. Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs

    A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

    Time frame: Throughout the study period (Day 1 to Day 361)

Secondary outcomes

  1. Percentage of Participants With 4-fold Rise in hSBA Titers Against N.Meningitidis Group B Strains at 1 Month After Last MenABCWY Dose(ABCWY Group-pooled Lots) and 1 Month After 2-dose(0,2-M) Schedule of rMenB+OMV NZ Relative to Baseline

    The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4; a post-vaccination hSBA titre ≥4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥LOD and \<LLOQ; a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule]) compared to Day 1 (Baseline)

  2. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose and 3-dose (0,2,6-M), 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY

    The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M ) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group,ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the MenB_0_2_6 group [3 dose schedule], MenB_0_6 group, ABCWY_Pooled group and Day 31 for the MenACWY group)

  3. Percentage of Blood Samples Without Bactericidal Serum Activity Using Enc-hSBA Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY

    The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2 dose schedule] and Day 31 for the MenACWY group)

  4. Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination Schedule for the MenB_0_2_6 Group [3 Dose], MenB_0_6 Group and Last MenABCWY Dose (Pooled Lots)

    The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

  5. Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

    The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group.

    Time frame: At 1 month after the vaccination schedule (Day 91 for MenB_0_2_6 group [2 dose schedule])

  6. Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

    The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains(M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group)

  7. Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

    The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).

    Time frame: At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2 dose schedule])

  8. Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

    The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for subjects with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titer ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)

  9. Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2 Months)

    The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titre ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre ≥ LLOQ.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 [2-dose schedule]) compared to Day 1 (baseline)

  10. hSBA Geometric Mean Titres (GMTs) Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

    The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

  11. hSBA GMTs Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

    The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs.

    Time frame: At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group[2-dose schedule])

  12. hSBA Geometric Mean Ratios (GMRs) for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

    The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)

  13. hSBA GMRs for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

    The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule]) compared to Day 1 (baseline)

  14. Percentage of Participants With hSBA Titers >= LLOQ for Each of the N. Meningitidis Serogroups A,C,W,Y at Day 1 and at 1 Month After the First and the Last MenABCWY Vaccination for ABCWY_Pooled Group and 1 Month After the MenACWY Vaccine for ACWY Group

    The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers \>= LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])

  15. Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First MenABCWY Dose for ABCWY_Pooled Group Compared to the MenACWY Vaccine for ACWY Group Relative to Baseline (Day 1)

    The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be ≥ 16. - If the pre-vaccination hSBA titer is ≥ LOD but \< LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is ≥ LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled group] and for ACWY Group) relative to baseline (Day 1)

  16. hSBA GMTs Against Each of the N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY_Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group

    The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])

  17. GMRs for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY _Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group

    The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose]) compared to baseline (Day 1)

  18. Total Immunoglobulin G (IgG) Antibodies Concentrations Against N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for ABCWY _Pooled Group and 1 Month After the MenACWY Vaccination for ACWY Group

    The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (ECL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). ECL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

    Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])

07

Results

Posted Mar 5, 2024

Participant flow

As pre-specified in protocol: * Participant flow, Baseline characteristics, Effectiveness and immunogenicity data are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. * Lot-to-lot consistency analysis data are presented for individual ABCWY lot groups (ABCWY-1, ABCWY-2 and ABCWY-3) as Lot-to-Lot assessment was limited to the objective on lot-to-lot consistency only.

Participant flow — Overall Study
MilestoneMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Started8979061657178
Abcwy-1 group005490
Abcwy-2 group005540
Abcwy-3 group005540
Completed7978111497163
Not completed1009516015
Withdrew: Adverse event76111
Withdrew: Lost to follow-up3236694
Withdrew: Protocol violation88161
Withdrew: Withdrawal by subject4638547
Withdrew: Migrated / moved from the study area6791
Withdrew: Other1011

Outcome measures

PrimaryPercentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.

Time frame:
At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY
Percentage of blood samplesMenB_0_2_6 GroupMenB_0_6 GroupACWY Group
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY13.314.479
Statistical analysis
  • MenB_0_2_6 Group vs ACWY Group · Ve (vaccine effectiveness): 83.2 · 97.5% CI 81.9 to 84.4
  • MenB_0_6 Group vs ACWY Group · Ve: 81.8 · 97.5% CI 80.4 to 83.1
PrimaryPercentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.

Time frame:
At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY
Percentage of blood samplesMenB_0_2_6 GroupACWY Group
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY16.879
Statistical analysis
  • MenB_0_2_6 Group vs ACWY Group · Ve: 78.7 · 97.5% CI 77.2 to 80.1
PrimaryPercentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.

Time frame:
At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)
Reported as:
Number · Percentage of participants
Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV
Percentage of participantsMenB_0_2_6 GroupMenB_0_6 Group
Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV93.4 ± 91.289.8 ± 87.2
PrimaryPercentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.

Time frame:
At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])
Reported as:
Number · Percentage of participants
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV
Percentage of participantsMenB_0_2_6 Group
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV84.8 ± 81.8
PrimaryGeometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWY

Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre-specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine.

Time frame:
At 1 month after the last vaccination of MenABCWY (Day 211)
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWY
TitersABCWY-1 GroupABCWY-2 GroupABCWY-3 Group
Men A336.4 (299.3 to 378.0)349.9 (311.5 to 393.0)390.4 (347.4 to 438.8)
Men C1036.7 (877.6 to 1224.5)1130.2 (958.1 to 1333.4)888.4 (752.1 to 1049.2)
Men W564.5 (497.9 to 639.9)635.5 (561.0 to 719.9)640.1 (564.6 to 725.6)
Men Y536.7 (464.5 to 620.2)623.9 (540.4 to 720.2)644.3 (557.6 to 744.6)
Statistical analysis
  • ABCWY-1 Group vs ABCWY-2 Group · Gmt ratio: 0.96 · 95% CI 0.84 to 1.10
  • ABCWY-1 Group vs ABCWY-3 Group · Gmt ratio: 0.86 · 95% CI 0.75 to 0.98
  • ABCWY-2 Group vs ABCWY-3 Group · Gmt ratio: 0.90 · 95% CI 0.78 to 1.02
  • ABCWY-1 Group vs ABCWY-2 Group · Gmt ratio: 0.92 · 95% CI 0.76 to 1.11
  • ABCWY-1 Group vs ABCWY-3 Group · Gmt ratio: 1.17 · 95% CI 0.97 to 1.41
  • ABCWY-2 Group vs ABCWY-3 Group · Gmt ratio: 1.27 · 95% CI 1.05 to 1.54
  • ABCWY-1 Group vs ABCWY-2 Group · Gmt ratio: 0.89 · 95% CI 0.77 to 1.02
  • ABCWY-1 Group vs ABCWY-3 Group · Gmt ratio: 0.88 · 95% CI 0.77 to 1.02
  • ABCWY-2 Group vs ABCWY-3 Group · Gmt ratio: 0.99 · 95% CI 0.86 to 1.14
  • ABCWY-1 Group vs ABCWY-2 Group · Gmt ratio: 0.86 · 95% CI 0.73 to 1.01
  • ABCWY-1 Group vs ABCWY-3 Group · Gmt ratio: 0.83 · 95% CI 0.71 to 0.98
  • ABCWY-2 Group vs ABCWY-3 Group · Gmt ratio: 0.97 · 95% CI 0.82 to 1.14
PrimaryPercentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to Baseline

Four-fold rise is defined as: If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be \>= 16 . If the pre-vaccination hSBA titer is \>= limit of detection (LOD) but \< LL of quantification (LLOQ), then post-vaccination hSBA titer should be \>= 4 times the LLOQ. If the pre-vaccination hSBA titer is \>= LLOQ, then post-vaccination hSBA titer should be \>= 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to Baseline
Percentage of participantsABCWY_PooledACWY Group
Men A97.0 (95.9 to 97.9)85.7 (77.8 to 91.6)
Men C97.2 (96.1 to 98.1)50.0 (40.5 to 59.5)
Men W97.0 (95.9 to 97.9)61.7 (52.2 to 70.6)
Men Y96.7 (95.6 to 97.7)69.7 (60.7 to 77.8)
Statistical analysis
  • ABCWY_Pooled vs ACWY Group · Difference in percentage of participants · Difference in percentage of participants: 11.29 · 95% CI 5.88 to 19.01
  • ABCWY_Pooled vs ACWY Group · Difference in percentage of participants: 47.22 · 95% CI 38.14 to 56.30
  • ABCWY_Pooled vs ACWY Group · Difference in percentage of participants: 35.31 · 95% CI 26.88 to 44.49
  • ABCWY_Pooled vs ACWY Group · Difference in percentage of participants: 26.99 · 95% CI 19.38 to 35.81
PrimaryPercentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)

The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)
Percentage of blood samplesABCWY_PooledACWY Group
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)17.479
Statistical analysis
  • ABCWY_Pooled vs ACWY Group · Ve: 77.9 · 95% CI 76.6 to 79.2
PrimaryPercentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV

The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV
Percentage of blood samplesMenB_0_2_6 GroupABCWY_Pooled
Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV83.182.5
Statistical analysis
  • MenB_0_2_6 Group vs ABCWY_Pooled · Difference in percentage of participants: -0.61 · 95% CI -1.25 to 0.03
PrimaryPercentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)

The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains tested for MenABCWY is above 65%.

Time frame:
At 1 month after the last vaccination of MenABCWY (Day 211)
Reported as:
Number · Percentage of participants
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)
Percentage of participantsABCWY_Pooled
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)84.1 ± 81.4
PrimaryNumber of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention Administration

Assessed solicited local adverse events were injection or administration site = pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the first study intervention administration occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Pain807819150367
Erythema908621611
Swelling878921711
Induration60641507
PrimaryNumber of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention Administration

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the second study intervention administration occurring at Day 61
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Pain71422420530
Erythema892651
Swelling992251
Induration671960
PrimaryNumber of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention Administration

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the third study intervention administration occurring at Day 181
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Pain6776761258126
Erythema1188716811
Swelling1078517613
Induration525711412
PrimaryNumber of Participants With Any Solicited Systemic AEs After the First Study Intervention Administration

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the first study intervention administration occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Systemic AEs After the First Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Fatigue42341482878
Nausea11211124227
Myalgia9210624213
Arthralgia567013317
Headache35833068169
Fever (C)1917553
PrimaryNumber of Participants With Any Solicited Systemic AEs After the Second Study Intervention Administration

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the second study intervention administration occurring at Day 61
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Systemic AEs After the Second Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Fatigue37222834536
Nausea104568518
Myalgia11046553
Arthralgia72332.0356
Headache30122333231
Fever (C)2212181
PrimaryNumber of Participants With Any Solicited Systemic AEs After the Third Study Intervention Administration

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During 7 days after the third study intervention administration occurring at Day 181
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Systemic AEs After the Third Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Fatigue37434160256
Nausea948414714
Myalgia10610916817
Arthralgia71531047
Headache30228450939
Fever (C)2123272
PrimaryNumber of Participants With Any Unsolicited AEs After the First Study Intervention Administration

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During the 30 days after the first study intervention administration occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited AEs After the First Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Number of Participants With Any Unsolicited AEs After the First Study Intervention Administration9012421729
PrimaryNumber of Participants With Any Unsolicited AEs After the Second Study Intervention Administration

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During the 30 days after the second study intervention administration occurring at Day 61
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration1068816015
PrimaryNumber of Participants With Any Unsolicited AEs After the Third Study Intervention Administration

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
During the 30 days after the third study intervention administration occurring at Day 181
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration969418319
PrimaryNumber of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs

A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Time frame:
Throughout the study period (Day 1 to Day 361)
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs
ParticipantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
SAEs2022255
AEs leading to withdrawal6441
AESIs1160
medically attended AEs23828847944
SecondaryPercentage of Participants With 4-fold Rise in hSBA Titers Against N.Meningitidis Group B Strains at 1 Month After Last MenABCWY Dose(ABCWY Group-pooled Lots) and 1 Month After 2-dose(0,2-M) Schedule of rMenB+OMV NZ Relative to Baseline

The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4; a post-vaccination hSBA titre ≥4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥LOD and \<LLOQ; a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule]) compared to Day 1 (Baseline)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers Against N.Meningitidis Group B Strains at 1 Month After Last MenABCWY Dose(ABCWY Group-pooled Lots) and 1 Month After 2-dose(0,2-M) Schedule of rMenB+OMV NZ Relative to Baseline
Percentage of participantsMenB_0_2_6 GroupABCWY_Pooled
fHbp (M14459) Ab74.7 (71.3 to 77.8)79.7 (76.5 to 82.7)
NadA (96217) Ab96.4 (94.7 to 97.6)92.7 (90.5 to 94.5)
NHBA (M13520) Ab58.6 (54.9 to 62.3)61.9 (58.2 to 65.6)
PorA (NZ98/254) Ab53.3 (49.5 to 57.0)42.2 (38.4 to 46.1)
SecondaryPercentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose and 3-dose (0,2,6-M), 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY

The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M ) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group,ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for the MenB_0_2_6 group [3 dose schedule], MenB_0_6 group, ABCWY_Pooled group and Day 31 for the MenACWY group)
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose and 3-dose (0,2,6-M), 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY
Percentage of blood samplesMenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY Group
Meningitis B M10713 Ab0.40.41.215.6
Meningitis B M08641 Ab6.66.28.096.6
Meningitis B M12898 Ab8.411.412.168.1
Meningitis B M09150 Ab5.28.512.673.0
Meningitis B M09401 Ab50.246.55798.0
Meningitis B M07463 Ab1.51.83.549
Meningitis B M10496 Ab54.447.968.9100.0
Meningitis B M14530 Ab2.11.63.2100.0
Meningitis B M15668 Ab0.82.20.887.8
Meningitis B M14028 Ab2.85.74.9100
Meningitis B M09909 Ab79.183.486.2100.0
Meningitis B M14385 Ab0.90.80.016.3
Meningitis B M07992 Ab0.40.00.40.0
Meningitis B M09155 Ab1.72.01.397.8
Meningitis B M13085 Ab13.527.526.669.3
Meningitis B M18303 Ab2.94.09.5100.0
Meningitis B M18711 Ab5.24.29.575.8
Meningitis B M15009 Ab11.820.531.886.5
Meningitis B M07773 Ab0.70.40.474.3
Meningitis B M09662 Ab61.450.866.395.8
Meningitis B M18483 Ab3.05.13.772.2
Meningitis B M11906 Ab23.730.339.984.7
Meningitis B M14987 Ab1.28.812.768.6
Meningitis B M12014 Ab0.40.71.267.4
Meningitis B M18200 Ab6.314.814.933.7
Meningitis B M08912 Ab0.40.00.00.0
Meningitis B M16748 Ab0.80.000.0
Meningitis B M08152 Ab22.425.332.866.8
Meningitis B M09973 Ab0.81.13.083.3
Meningitis B M15352 Ab8.98.417.897.0
Meningitis B M15165 Ab0.01.22.192.9
Meningitis B M08127 Ab0.70.40.784.3
Meningitis B M18347 Ab45.450.951.882.1
Meningitis B M12500 Ab0.92.42.595.3
Meningitis B M07499 Ab70.775.780.1100.0
Meningitis B M09960 Ab1.2003.0
Meningitis B M18045 Ab00.4092.7
Meningitis B M10548 Ab8.111.912.574.1
Meningitis B M09354 Ab1.21.3080.0
Meningitis B M11051 Ab61.064.266.797.8
Meningitis B M10104 Ab58.752.363.597.6
Meningitis B M13361 Ab0.80.40.485.3
Meningitis B M11042 Ab19.825.533.585.7
Meningitis B M18467 Ab1.20.40.878.7
Meningitis B M11113 Ab30.139.549.575.2
Meningitis B M07253 Ab34.733.850.286.4
Meningitis B M07356 Ab0.401.141.4
Meningitis B M10710 Ab1.62.01.492.5
Meningitis B M17147 Ab2.35.42.3100
Meningitis B M14401 Ab1.70.41.283.7
Meningitis B M14293 Ab45.825.145.295.7
Meningitis B M08540 Ab1.60.8038.2
Meningitis B M07960 Ab3.64.11.894.9
Meningitis B M16135 Ab01.70.895.1
Meningitis B M14548 Ab2.63.43.294.7
Meningitis B M09181 Ab00.40.472.1
Meningitis B M14224 Ab0.40.4082.5
Meningitis B M07452 Ab2.78.117.185.1
Meningitis B M13520 Ab3.20.9066.7
Meningitis B M09385 Ab0.41.6046.9
Meningitis B M14881 Ab4.25.81095
Meningitis B M13252 Ab0.71.20.498
Meningitis B M07818 Ab0.40.81.390.7
Meningitis B M09914 Ab85.486.888.398
Meningitis B M15083 Ab51.456.76184.5
Meningitis B M11290 Ab61.461.767.4100
Meningitis B M14988 Ab0.401.260
Meningitis B M10536 Ab19.714.314.391.7
Meningitis B M08959 Ab0.80.41.985.1
Meningitis B M08785 Ab0.80.40.453.8
Meningitis B M07245 Ab000.923.3
Meningitis B M19315 Ab3.83.19.579.4
Meningitis B M14376 Ab01.4092.7
Meningitis B M08994 Ab2.57.66.962.7
Meningitis B M11646 Ab01.3283.3
Meningitis B M13362 Ab00.40.481.6
Meningitis B M08080 Ab27.44151.685.7
Meningitis B M08370 Ab2.31.53.797.7
Meningitis B M08129 Ab4.14.7771.4
Meningitis B M07111 Ab0.41.20.790.9
Meningitis B M07537 Ab95.995.997.7100
Meningitis B M13438 Ab1.20.8016
Meningitis B M10661 Ab22.92.997
Meningitis B M10920 Ab29.127.837.891.2
Meningitis B M15564 Ab0.40.70.877.5
Meningitis B M10934 Ab0.40.80.8100
Meningitis B M09400 Ab0.81.80.497.4
Meningitis B M08781 Ab71.974.478.2100
Meningitis B M09173 Ab0.40.40.895.2
Meningitis B M14113 Ab15.421.222100
Meningitis B M08389 Ab10.7711.787.2
Meningitis B M16822 Ab67.876.482.2100
Meningitis B M10995 Ab5.217.830.685.1
Meningitis B M08780 Ab1.30.81.592.5
Meningitis B M09910 Ab1.61.21.293
Meningitis B M08320 Ab33.639.743.387
Meningitis B M14879 Ab2.12.16.121.3
Meningitis B M09345 Ab19.320.133.481.2
Meningitis B M14594 Ab20.827.441.297.7
Meningitis B M07621 Ab1.21.21.177.5
Meningitis B M13568 Ab5.43.83.995
Meningitis B M18017 Ab0.401.696.8
Meningitis B M08420 Ab0.80.41.695
Meningitis B M07959 Ab1.72.51.797.1
Meningitis B M06970 Ab19.617.630.285.7
Meningitis B M10491 Ab5.48.41782.1
Meningitis B M13569 Ab0.92.91.296.8
Meningitis B M10182 Ab0.4000
Meningitis B M13547 Ab2.474.747.7
Meningitis B M15276 Ab0.401.587.8
SecondaryPercentage of Blood Samples Without Bactericidal Serum Activity Using Enc-hSBA Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY

The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2 dose schedule] and Day 31 for the MenACWY group)
Reported as:
Number · Percentage of blood samples
Percentage of Blood Samples Without Bactericidal Serum Activity Using Enc-hSBA Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY
Percentage of blood samplesMenB_0_2_6 GroupACWY Group
Meningitis B M10713 Ab1.915.6
Meningitis B M08641 Ab11.296.6
Meningitis B M12898 Ab12.469
Meningitis B M09150 Ab9.368.6
Meningitis B M09401 Ab4798
Meningitis B M07463 Ab2.649
Meningitis B M10496 Ab50.5100
Meningitis B M14530 Ab3.9100
Meningitis B M15668 Ab0.487.8
Meningitis B M14028 Ab5.4100
Meningitis B M09909 Ab82100
Meningitis B M14385 Ab016.3
Meningitis B M07992 Ab00
Meningitis B M09155 Ab2.597.8
Meningitis B M13085 Ab2166.4
Meningitis B M18303 Ab9.1100
Meningitis B M18711 Ab7.775.8
Meningitis B M15009 Ab22.286.5
Meningitis B M07773 Ab1.174.3
Meningitis B M09662 Ab58.195.8
Meningitis B M18483 Ab4.377.3
Meningitis B M11906 Ab38.885.3
Meningitis B M14987 Ab10.762.3
Meningitis B M12014 Ab0.763.2
Meningitis B M18200 Ab12.134.4
Meningitis B M08912 Ab00
Meningitis B M16748 Ab00
Meningitis B M08152 Ab35.667.2
Meningitis B M09973 Ab1.583.3
Meningitis B M15352 Ab11.997
Meningitis B M15165 Ab0.892.9
Meningitis B M08127 Ab0.484.3
Meningitis B M18347 Ab60.580.4
Meningitis B M12500 Ab3.495.3
Meningitis B M07499 Ab81.1100
Meningitis B M09960 Ab4.43
Meningitis B M18045 Ab092.7
Meningitis B M10548 Ab11.974.1
Meningitis B M09354 Ab0.480
Meningitis B M11051 Ab68.997.8
Meningitis B M10104 Ab61.897.6
Meningitis B M13361 Ab0.485.3
Meningitis B M11042 Ab30.184.2
Meningitis B M18467 Ab0.478.7
Meningitis B M11113 Ab43.175.6
Meningitis B M07253 Ab43.385.3
Meningitis B M07356 Ab041.4
Meningitis B M10710 Ab2.292.5
Meningitis B M17147 Ab5.1100
Meningitis B M14401 Ab0.883.7
Meningitis B M14293 Ab36.495.7
Meningitis B M08540 Ab0.438.2
Meningitis B M07960 Ab4.194.9
Meningitis B M16135 Ab0.895.1
Meningitis B M14548 Ab2.894.7
Meningitis B M09181 Ab072.1
Meningitis B M14224 Ab0.782.5
Meningitis B M07452 Ab13.585.1
Meningitis B M13520 Ab0.966.7
Meningitis B M09385 Ab2.246.9
Meningitis B M14881 Ab14.795
Meningitis B M13252 Ab3.198
Meningitis B M07818 Ab0.490.7
Meningitis B M09914 Ab87.798
Meningitis B M15083 Ab63.778
Meningitis B M11290 Ab70.5100
Meningitis B M14988 Ab0.460
Meningitis B M10536 Ab23.291.7
Meningitis B M08959 Ab0.485.1
Meningitis B M08785 Ab0.453.8
Meningitis B M07245 Ab023.3
Meningitis B M19315 Ab6.379.4
Meningitis B M14376 Ab092.7
Meningitis B M08994 Ab8.955.7
Meningitis B M11646 Ab1.683.3
Meningitis B M13362 Ab1.581.6
Meningitis B M08080 Ab46.887.1
Meningitis B M08370 Ab3.997.7
Meningitis B M08129 Ab7.471.4
Meningitis B M07111 Ab0.490.9
Meningitis B M07537 Ab96.4100
Meningitis B M13438 Ab0.416
Meningitis B M10661 Ab2.797
Meningitis B M10920 Ab50.291.2
Meningitis B M15564 Ab0.877.5
Meningitis B M10934 Ab0100
Meningitis B M09400 Ab1.197.4
Meningitis B M08781 Ab75.8100
Meningitis B M09173 Ab095.2
Meningitis B M14113 Ab28.3100
Meningitis B M08389 Ab1.986.7
Meningitis B M16822 Ab85100
Meningitis B M10995 Ab16.385.1
Meningitis B M08780 Ab0.892.5
Meningitis B M09910 Ab1.293
Meningitis B M08320 Ab45.186.8
Meningitis B M14879 Ab3.323.2
Meningitis B M09345 Ab32.374.9
Meningitis B M14594 Ab35.897.7
Meningitis B M07621 Ab0.477.5
Meningitis B M13568 Ab9.795
Meningitis B M18017 Ab096.8
Meningitis B M08420 Ab0.895
Meningitis B M07959 Ab1.297.1
Meningitis B M06970 Ab28.890.6
Meningitis B M10491 Ab16.182.1
Meningitis B M13569 Ab0.496.8
Meningitis B M10182 Ab00
Meningitis B M13547 Ab547.7
Meningitis B M15276 Ab0.487.8
SecondaryPercentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination Schedule for the MenB_0_2_6 Group [3 Dose], MenB_0_6 Group and Last MenABCWY Dose (Pooled Lots)

The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)
Reported as:
Number · Percentage of participants
Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination Schedule for the MenB_0_2_6 Group [3 Dose], MenB_0_6 Group and Last MenABCWY Dose (Pooled Lots)
Percentage of participantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_Pooled
>=50% killed strains98.7 ± 97.798.5 ± 97.498 ± 96.8
>=55% killed strains98.4 ± 97.297.4 ± 96.196.8 ± 95.4
>=60% killed strains97.8 ± 96.696.8 ± 95.395.2 ± 93.5
>=65% killed strains96.5 ± 94.993.6 ± 91.790.1 ± 87.8
>=70% killed strains93.4 ± 91.589.8 ± 87.584.1 ± 81.4
>=75% killed strains86.8 ± 84.382.2 ± 79.474.7 ± 71.5
>=80% killed strains79.2 ± 76.275.5 ± 72.466 ± 62.6
>=85% killed strains62.8 ± 59.360.4 ± 56.950.1 ± 46.6
>=90% killed strains43.7 ± 40.241.3 ± 37.932.1 ± 28.9
>=95% killed strains22.5 ± 19.721 ± 18.313.7 ± 11.4
100% killed strains10 ± 88.4 ± 6.66.1 ± 4.6
SecondaryPercentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group.

Time frame:
At 1 month after the vaccination schedule (Day 91 for MenB_0_2_6 group [2 dose schedule])
Reported as:
Number · Percentage of participants
Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
Percentage of participantsMenB_0_2_6 Group
>=50% killed strains98.6 ± 97.5
>=55% killed strains97.7 ± 96.5
>=60% killed strains96.5 ± 95
>=65% killed strains92.2 ± 90.1
>=70% killed strains84.8 ± 82.2
>=75% killed strains75.7 ± 72.6
>=80% killed strains66.7 ± 63.3
>=85% killed strains49.7 ± 46.2
>=90% killed strains33.8 ± 30.6
>=95% killed strains16.2 ± 13.8
100% killed strains7.7 ± 6
SecondaryPercentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains(M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
Percentage of participantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_Pooled
fHbp (M14459) Ab, Day 14.9 (3.5 to 6.7)3.4 (2.2 to 5)5.4 (3.9 to 7.2)
fHbp (M14459) Ab, Day 21197.4 (95.9 to 98.4)94.6 (92.7 to 96.2)95.9 (94.2 to 97.2)
NadA (96217) Ab, Day 16.2 (4.6 to 8.2)4.4 (3.0 to 6.1)6.2 (4.6 to 8.1)
NadA (96217) Ab, Day 211100 (99.5 to 100)98 (96.7 to 98.9)96.2 (94.5 to 97.5)
NHBA (M13520) Ab, Day 123.2 (20.3 to 26.4)20.9 (18 to 24.1)18.5 (15.8 to 21.4)
NHBA (M13520) Ab, Day 21197.0 (95.4 to 98.1)97.5 (96.0 to 98.5)95.3 (93.5 to 96.7)
PorA (NZ98/254) Ab, Day 12.3 (1.3 to 3.7)1.4 (0.7 to 2.6)2.1 (1.2 to 3.4)
PorA (NZ98/254) Ab, Day 21185.8 (82.9 to 88.4)82.6 (79.5 to 85.4)75.3 (72.0 to 78.5)
Composite Response, Day=11.1 (0.5 to 2.2)0.6 (0.2 to 1.4)1.1 (0.5 to 2.1)
Composite Response, Day=21183.3 (80.3 to 86.1)80.7 (77.5 to 83.6)71.4 (67.9 to 74.7)
SecondaryPercentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).

Time frame:
At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2 dose schedule])
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
Percentage of participantsMenB_0_2_6 Group
fHbp (M14459) Ab, Day 14.9 (3.5 to 6.7)
fHbp (M14459) Ab, Day 9192.9 (90.9 to 94.7)
NadA (96217) Ab, Day 16.2 (4.6 to 8.2)
NadA (96217) Ab, Day 9199.5 (98.6 to 99.9)
NHBA, Day 123.2 (20.3 to 26.4)
NHBA (M13520) Ab, Day 9196.1 (94.5 to 97.4)
PorA N (NZ98/254) Ab, Day 12.3 (1.3 to 3.7)
PorA N (NZ98/254) Ab, Day 9180 (76.9 to 82.8)
Composite Response, Day=11.1 (0.5 to 2.2)
Composite Response, Day=9175.5 (72.3 to 78.6)
SecondaryPercentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for subjects with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titer ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
Percentage of participantsMenB_0_2_6 GroupMenB_0_6 GroupABCWY_Pooled
fHbp (M14459) Ab86.7 (84.0 to 89.2)82.4 (79.4 to 85.2)78.9 (75.7 to 81.8)
NadA (96217) Ab98.7 (97.5 to 99.4)95.3 (93.4 to 96.7)92.3 (90.1 to 94.1)
NHBA (M13520) Ab66.9 (63.2 to 70.4)69.5 (65.9 to 72.8)61.1 (57.5 to 64.7)
PorA (NZ98/254) Ab56.5 (52.6 to 60.4)57.2 (53.4 to 61.0)42.4 (38.7 to 46.2)
SecondaryPercentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2 Months)

The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titre ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre ≥ LLOQ.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 [2-dose schedule]) compared to Day 1 (baseline)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2 Months)
Percentage of participantsMenB_0_2_6 Group
fHbp (M14459) Ab74.6 (71.3 to 77.7)
NadA (96217) Ab96.3 (94.7 to 97.6)
NHBA (M13520) Ab58.5 (54.8 to 62.0)
PorA (NZ98/254) Ab53.5 (49.7 to 57.1)
SecondaryhSBA Geometric Mean Titres (GMTs) Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titres (GMTs) Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
TitersMenB_0_2_6 GroupMenB_0_6 GroupABCWY_Pooled
fHbp (M14459) Ab, Day 12.8 (2.7 to 2.8)2.7 (2.6 to 2.8)2.8 (2.7 to 2.9)
fHbp (M14459) Ab, Day 21130.8 (28.3 to 33.5)28.1 (25.9 to 30.6)25 (23 to 27.1)
NadA (96217) Ab, Day 18.4 (8.1 to 8.6)8.3 (8 to 8.6)8.5 (8.2 to 8.8)
NadA (96217) Ab, Day 211267.2 (243.7 to 293)215.1 (196.2 to 235.9)150.6 (137.3 to 165.2)
NHBA (M13520) Ab, Day 13.4 (3.1 to 3.7)3.2 (3 to 3.5)3.1 (2.8 to 3.4)
NHBA (M13520) Ab, Day 21130.6 (27.7 to 33.7)33.2 (30.2 to 36.6)25.2 (22.9 to 27.8)
PorA (NZ98/254) Ab, Day 13.2 (3.1 to 3.2)3.1 (3 to 3.2)3.1 (3.1 to 3.2)
PorA (NZ98/254) Ab, Day 21118.1 (16.3 to 20.1)17.7 (15.9 to 19.6)12.9 (11.6 to 14.4)
SecondaryhSBA GMTs Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs.

Time frame:
At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group[2-dose schedule])
Reported as:
Geometric mean · Titers
hSBA GMTs Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
TitersMenB_0_2_6 Group
fHbp (M14459) Ab, Day 12.8 (2.7 to 2.8)
fHbp (M14459) Ab, Day 9120.9 (18.9 to 23.1)
NadA (96217) Ab, Day 18.4 (8.1 to 8.6)
NadA (96217) Ab, Day 91178.5 (161.7 to 197.2)
NHBA (M13520) Ab, Day 13.4 (3.1 to 3.7)
NHBA (M13520) Ab, Day 9127.2 (24.1 to 30.6)
PorA (NZ98/254) Ab, Day 13.2 (3.1 to 3.2)
PorA (NZ98/254) Ab, Day 9117.1 (15.2 to 19.3)
SecondaryhSBA Geometric Mean Ratios (GMRs) for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)
Reported as:
Geometric mean · Ratio
hSBA Geometric Mean Ratios (GMRs) for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
RatioMenB_0_2_6 GroupMenB_0_6 GroupABCWY_Pooled
fHbp (M14459) Ab11.2 (10.3 to 12.2)10.5 (9.6 to 11.4)9 (8.2 to 9.8)
NadA (96217) Ab32.1 (29.1 to 35.3)25.8 (23.5 to 28.4)17.7 (16 to 19.4)
NHBA (M13520) Ab9.1 (8.2 to 10.1)10.6 (9.5 to 11.7)8.2 (7.4 to 9.1)
PorA (NZ98/254) Ab5.8 (5.2 to 6.5)5.8 (5.2 to 6.4)4.1 (3.7 to 4.6)
SecondaryhSBA GMRs for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule]) compared to Day 1 (baseline)
Reported as:
Geometric mean · Ratio
hSBA GMRs for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
RatioMenB_0_2_6 Group
fHbp (M14459) Ab7.7 (6.9 to 8.5)
NadA (96217) Ab21.7 (19.5 to 24)
NHBA (M13520) Ab8 (7.1 to 9)
PorA (NZ98/254) Ab5.5 (4.9 to 6.2)
SecondaryPercentage of Participants With hSBA Titers >= LLOQ for Each of the N. Meningitidis Serogroups A,C,W,Y at Day 1 and at 1 Month After the First and the Last MenABCWY Vaccination for ABCWY_Pooled Group and 1 Month After the MenACWY Vaccine for ACWY Group

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers \>= LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >= LLOQ for Each of the N. Meningitidis Serogroups A,C,W,Y at Day 1 and at 1 Month After the First and the Last MenABCWY Vaccination for ABCWY_Pooled Group and 1 Month After the MenACWY Vaccine for ACWY Group
Percentage of participantsABCWY_PooledACWY Group
Men A, Day 19.2 (7.7 to 10.8)11.7 (6.8 to 18.3)
Men A, Day 3179.5 (71.7 to 86.1)90.2 (83.9 to 94.7)
Men A, Day 21198.6 (97.9 to 99.2)—
Men C, Day 129.8 (27.5 to 32.2)28.8 (21.4 to 37.1)
Men C, Day 3174.8 (66.8 to 81.8)64.0 (55.3 to 72.0)
Men C, Day 21199.6 (99.1 to 99.8)—
Men W, Day 112.6 (10.9 to 14.4)12.9 (7.8 to 19.6)
Men W, Day 3180.3 (72.8 to 86.5)69.3 (60.9 to 76.9)
Men W, Day 21199.2 (98.7 to 99.6)—
Men Y, Day 112.2 (10.6 to 14.0)13.5 (8.3 to 20.2)
Men Y, Day 3182.2 (75.0 to 88.0)80.0 (72.4 to 86.3)
Men Y, Day 21199.2 (98.7 to 99.6)—
SecondaryPercentage of Participants With 4-fold Rise in hSBA Titers for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First MenABCWY Dose for ABCWY_Pooled Group Compared to the MenACWY Vaccine for ACWY Group Relative to Baseline (Day 1)

The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be ≥ 16. - If the pre-vaccination hSBA titer is ≥ LOD but \< LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is ≥ LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled group] and for ACWY Group) relative to baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First MenABCWY Dose for ABCWY_Pooled Group Compared to the MenACWY Vaccine for ACWY Group Relative to Baseline (Day 1)
Percentage of participantsABCWY_PooledACWY Group
Men A74.0 (65.5 to 81.4)86.0 (78.8 to 91.5)
Men C66.9 (58.4 to 74.6)56.7 (47.9 to 65.2)
Men W74.1 (66.0 to 81.2)66.2 (57.6 to 74.1)
Men Y76.0 (68.3 to 82.7)72.1 (63.9 to 79.4)
SecondaryhSBA GMTs Against Each of the N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY_Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
Reported as:
Geometric mean · Titers
hSBA GMTs Against Each of the N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY_Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group
TitersABCWY_PooledACWY Group
Men A, Day 111.1 (10.3 to 11.9)12.7 (10.9 to 14.8)
Men A, Day 31175.3 (121.2 to 253.3)474.8 (331.3 to 680.3)
Men A, Day 211352.0 (322.0 to 384.7)—
Men C, Day 112.0 (10.9 to 13.3)11.4 (9.1 to 14.3)
Men C, Day 31674.8 (355.9 to 1279.4)379.0 (204.4 to 703.0)
Men C, Day 2111162.5 (1015.7 to 1330.5)—
Men W, Day 18.0 (7.4 to 8.7)7.4 (6.2 to 8.9)
Men W, Day 31374.0 (243.4 to 574.8)194.3 (128.3 to 294.2)
Men W, Day 211666.5 (603.2 to 736.3)—
Men Y, Day 19.3 (8.7 to 10.0)9.9 (8.6 to 11.5)
Men Y, Day 31375.4 (246.9 to 570.7)320.9 (213.8 to 481.7)
Men Y, Day 211655.9 (587.0 to 733.0)—
SecondaryGMRs for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY _Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose]) compared to baseline (Day 1)
Reported as:
Geometric mean · Ratio
GMRs for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY _Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group
RatioABCWY_PooledACWY Group
Men A, Day 3111.8 (7.9 to 17.7)31.8 (21.4 to 47.1)
Men A, Day 21131.2 (28.3 to 34.5)—
Men C, Day 3130.9 (16.9 to 56.2)22.9 (12.8 to 41.1)
Men C, Day 21196.9 (84.5 to 111.1)—
Men W, Day 3132.9 (21.7 to 50.0)23.2 (15.5 to 34.7)
Men W, Day 21183.8 (74.9 to 93.8)—
Men Y, Day 3128.1 (18.3 to 43.2)25.6 (16.9 to 38.8)
Men Y, Day 21170.2 (62.3 to 79.1)—
SecondaryTotal Immunoglobulin G (IgG) Antibodies Concentrations Against N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for ABCWY _Pooled Group and 1 Month After the MenACWY Vaccination for ACWY Group

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (ECL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). ECL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Time frame:
At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
Reported as:
Geometric mean · microgram per milliliter(µg/mL)
Total Immunoglobulin G (IgG) Antibodies Concentrations Against N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for ABCWY _Pooled Group and 1 Month After the MenACWY Vaccination for ACWY Group
microgram per milliliter(µg/mL)ACWY GroupABCWY_Pooled
Men A, Day 12.3 (2.0 to 2.7)1.9 (1.6 to 2.2)
Men A, Day 3153.7 (40.8 to 70.7)18.1 (13.8 to 23.8)
Men A, Day 211—30.2 (23.3 to 39.2)
Men C, Day 10.8 (0.7 to 1.0)0.7 (0.6 to 0.8)
Men C, Day 3113.8 (10.4 to 18.4)15.5 (11.6 to 20.7)
Men C, Day 211—17.0 (13.1 to 22.0)
Men W, Day 10.6 (0.5 to 0.7)0.5 (0.4 to 0.6)
Men W, Day 318.4 (6.0 to 11.6)9.1 (6.5 to 12.8)
Men W, Day 211—21.7 (16.0 to 29.5)
Men Y, Day 10.9 (0.8 to 1.0)0.9 (0.7 to 1.0)
Men Y, Day 3114.3 (10.2 to 19.8)12.9 (9.2 to 18.0)
Men Y, Day 211—26.3 (19.6 to 35.4)

Adverse events

Collected over SAEs and Non-serious AEs (Other AEs) were collected through the entire period of the study (from Day 1 up to study end [Day 361]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenB_0_2_6 Group1/897 (0.1%)20/897 (2.2%)876/897 (97.7%)
MenB_0_6 Group1/906 (0.1%)22/906 (2.4%)872/906 (96.2%)
ACWY Group0/178 (0%)5/178 (2.8%)173/178 (97.2%)
ABCWY-1 Group0/549 (0%)8/549 (1.5%)529/549 (96.4%)
ABCWY-2 Group0/554 (0%)9/554 (1.6%)537/554 (96.9%)
ABCWY-3 Group0/554 (0%)8/554 (1.4%)544/554 (98.2%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventMenB_0_2_6 GroupMenB_0_6 GroupACWY GroupABCWY-1 GroupABCWY-2 GroupABCWY-3 Group
Mental disorderPsychiatric disorders0/8970/9060/178—1/1—
Chest painGeneral disorders0/8970/9061/1780/5490/5540/554
ConcussionInjury, poisoning and procedural complications3/8970/9061/1780/5491/5540/554
Troponin T increasedInvestigations0/8970/9061/1780/5490/5540/554
Testis cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8970/9061/178———
AphasiaNervous system disorders0/8970/9061/1780/5490/5540/554
DizzinessNervous system disorders0/8970/9061/1780/5490/5540/554
DysarthriaNervous system disorders0/8970/9061/1780/5490/5540/554
Speech disorderNervous system disorders0/8970/9061/1780/5490/5540/554
DepressionPsychiatric disorders0/8972/9061/1780/5490/5540/554
Most frequent other events
Showing 10 of 549
Most frequent other events
EventMenB_0_2_6 GroupMenB_0_6 GroupACWY GroupABCWY-1 GroupABCWY-2 GroupABCWY-3 Group
Lower limb fractureInjury, poisoning and procedural complications1/8970/9060/178—1/1—
Administration site painGeneral disorders851/897853/906149/178515/549522/554524/554
FatigueGeneral disorders604/897579/906105/178352/549356/554358/554
HeadacheNervous system disorders578/897525/90697/178300/549309/554320/554
NauseaGastrointestinal disorders245/897204/90645/178121/549138/554139/554
MyalgiaMusculoskeletal and connective tissue disorders240/897209/90630/178122/549132/554130/554
Administration site erythemaGeneral disorders209/897157/90621/178112/549115/55494/554
Administration site swellingGeneral disorders202/897158/90622/178101/549109/55495/554
ArthralgiaMusculoskeletal and connective tissue disorders154/897127/90625/17884/54976/55476/554
Administration site indurationGeneral disorders138/897113/90617/17873/54978/55472/554

Baseline characteristics

As pre-specified in the protocol, data reported in the Baseline characteristics are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.

Age, Continuous
Age, Continuous(years)MenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY GroupTotal
Mean16.5 ± 4.716.5 ± 4.716.5 ± 4.716.9 ± 4.616.5 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)MenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY GroupTotal
Female4644469331001943
Male433460724781695
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MenB_0_2_6 GroupMenB_0_6 GroupABCWY_PooledACWY GroupTotal
American Indian or Alaska Native553013
Asian4360719183
Black or African American3329596127
Native Hawaiian or Other Pacific Islander31307
White79679114921623241
Other, Unspecified172029167
08

Study locations

112 sites
  • GSK Investigational Site
    Chandler, Arizona 85286, United States
  • GSK Investigational Site
    Glendale, Arizona 85308, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Bell Gardens, California 90201, United States
  • GSK Investigational Site
    Canoga Park, California 91304, United States
  • GSK Investigational Site
    Garden Grove, California 92840, United States
  • GSK Investigational Site
    Inglewood, California 90301, United States
  • GSK Investigational Site
    Los Gatos, California 95032, United States
  • GSK Investigational Site
    Cutler Bay, Florida 33157, United States
  • GSK Investigational Site
    Lake City, Florida 32055, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33165, United States
  • GSK Investigational Site
    Miami, Florida 33174, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Orlando, Florida 32801, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Orlando, Florida 32808, United States
  • GSK Investigational Site
    Oviedo, Florida 32765, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Adairsville, Georgia 30103, United States
  • GSK Investigational Site
    Buford, Georgia 30519, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Hinesville, Georgia 31313, United States
  • GSK Investigational Site
    Nampa, Idaho 83686, United States
  • GSK Investigational Site
    Oak Brook, Illinois 60523, United States
  • GSK Investigational Site
    Wichita, Kansas 67205, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Louisville, Kentucky 40243, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Beverly, Massachusetts 01915, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02721, United States
  • GSK Investigational Site
    Grosse Pointe Woods, Michigan 48236, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Petal, Mississippi 39465, United States
  • GSK Investigational Site
    Missoula, Montana 59804, United States
  • GSK Investigational Site
    Missoula, Montana 59808, United States
  • GSK Investigational Site
    Bronx, New York 10455, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Dayton, Ohio 45419, United States
  • GSK Investigational Site
    Grants Pass, Oregon 97527, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29405, United States
  • GSK Investigational Site
    West Columbia, South Carolina 29169, United States
  • GSK Investigational Site
    Laredo, Texas 78041, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Kaysville, Utah 84037, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Murray, Utah 84107, United States
  • GSK Investigational Site
    Orem, Utah 84057, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
  • GSK Investigational Site
    Syracuse, Utah 84075, United States
  • GSK Investigational Site
    Falls Church, Virginia 22044, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
  • GSK Investigational Site
    Suffolk, Virginia 23435, United States
  • GSK Investigational Site
    Cheney, Washington 99004, United States
  • GSK Investigational Site
    Spokane, Washington 99202, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Gold Coast, Queensland 4222, Australia
  • GSK Investigational Site
    Taringa, Queensland 4068, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3010, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Calgary, Alberta T3B 6A8, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4H4, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    London, Ontario N5W 6A2, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Toronto, Ontario M9V 4B4, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Québec City, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Québec, G1V 4G2, Canada
  • GSK Investigational Site
    Ceske Budejovice, 37008, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 02, Czechia
  • GSK Investigational Site
    Jindrichuv Hradec, 37701, Czechia
  • GSK Investigational Site
    Kladno, 272 80, Czechia
  • GSK Investigational Site
    Melnik, 27601, Czechia
  • GSK Investigational Site
    Pardubice, 53003, Czechia
  • GSK Investigational Site
    Pardubice, 53009, Czechia
  • GSK Investigational Site
    Praha 6, 160 00, Czechia
  • GSK Investigational Site
    Pribram, 261 01, Czechia
  • GSK Investigational Site
    Trutnov, 541 01, Czechia
  • GSK Investigational Site
    Tynec nad Sazavou, 257 41, Czechia
  • GSK Investigational Site
    České Budejovice, 370 06, Czechia
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tallinn, 10617, Estonia
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland

Showing the first 100 of 112 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2022, 24 months.

Results were first posted in Mar 2024, 1 year 5 months after primary completion. A results delay was requested in Sep 2023.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 24 months is above that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 6, 2020
StartActual
Aug 14, 2020
Primary completionActual
Sep 13, 2022
CompletionActual
Sep 13, 2022
Results delay requested
Sep 4, 2023
Results first posted
Mar 5, 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04502693
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 6, 2020
Start date
Aug 14, 2020
Primary completion
Sep 13, 2022
Completion
Sep 13, 2022
Results posted
Mar 5, 2024
Last update
Mar 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 4CMenB vaccine · MenACWY

Start the discussion